Possible bone-preserving capacity of high-dose intramuscular depot estrogen as compared to orchidectomy in the treatment of patients with prostatic carcinoma

Prostate

Volumn 31, Issue 3, 1997, Pages 193-197

  Carlström, Kjell ^a   Stege, Reinhard ^a   Henriksson, Peter ^b   Grande, Mirtha ^a   Gunnarsson, Per Olov ^c   Pousette, Åke ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Sodertalje Hosp Karolinska Inst ^*  (Sweden)

Author keywords

bone mineral; car diovascular effects; estrogen treatment; orchidectomy; prostatic cancer

Indexed keywords

ESTROGEN; OSTEOCALCIN; POLYESTRADIOL PHOSPHATE; PROCOLLAGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; BONE MASS; BONE TURNOVER; CASTRATION; CLINICAL ARTICLE; ELDERLY CARE; ESTROGEN THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN CROSS LINKING; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE AND BONES; CARCINOMA; COLLAGEN; DELAYED-ACTION PREPARATIONS; ESTRADIOL; ESTRADIOL CONGENERS; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 0030985314     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19970515)31:3<193::AID-PROS8>3.0.CO;2-M     Document Type: Article

References (21)

1. Stege R, Carlström K, Collste L, Eriksson A, Henriksson P, Pousette Å, von Schoultz B: Single drug parenteral estrogen treatment in prostatic cancer: A study of different initial and maintenance dose regimens. Prostate 14:183-188, 1989.
2. Stege R, Carlström K, Henriksson P: Parenteral oestrogen seems to be a cardiovascular safe therapy of patients with prostatic cancer. Scand J Urol Nephrol [Suppl] 135:56, 1991.
3. Henriksson P, Blombäck M, Eriksson A, Stege R, Carlström K: Effects of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma. Br J Urol 65:282-285, 1990.
4. Von Schoultz B, Carlström K, Collste L, Eriksson A, Henriksson P, Pousette A, Stege R: Estrogen therapy and liver function - Metabolic effects of oral and parenteral administration. Prostate 14:389-395, 1989.
5. Stege R, Fröhlander N, Carlström K, Pousette Å, von Schoultz B: Steroid-sensitive proteins, growth hormone, and somatiomedin C in prostatic cancer: Effects of parenteral and oral estrogen therapy. Prostate 10: 333-338, 1987.
6. Stege R, Carlström K, Collste L, Eriksson A, Hensriksson P, Pousette Å: Single drug polyestradiol phosphate therapy in prostatic cancer. Am J Clin Oncol [Suppl] 11:1021-1023, 1988.
7. Haapiainen R, Rannikko S, Alfthan O, Finnprostate Group: Comparison of primary orchietomy and polyestradiol phosphate in the treatment of advanced prostatic cancer. Br J Urol 66:94-97, 1990.
8. Clarke NW, McClure J, George NJ: Preferential preservation of bone mineralization by LHRH agonists in the treatment of metastatic prostate cancer. Eur J Urol 19: 114-117, 1991.
9. 6-GnRH). J Clin Endocrinol Metab 76:288-290, 1993.
10. Tenover J: Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 75:1092-1098, 1992.
11. Eriksson S, Eriksson A, Stege R, Carlström K: Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int 57:97-99, 1995.
12. Södergård R, Bäckström T, Shanbag V, Carstensen H: Calculation of free and bound fractions of testosterone and estradiol-17β to plasma proteins at body temperature. J Steroid Biochem 18:801-804, 1982.
13. Eriksen EF, Charles P, Melsen F, Mosekilde L, Risteli L, Risteli J: Serum markers of type I collagen formation and degradation in metabolic bone disease: Correlation with bone histomorphometry. J Bone Miner Res 8:127-132, 1993.
14. Kylmälä T, Tammela T, Risteli L, Risteli J, Taube T, Elomaa I: Evaluation of the effect of oral clodronate on skeletal metastases with type I collagen metabolites. A controlled trial of the Finnish prostate cancer group. Eur J Cancer Clin Oncol 29:821-825, 1993.
15. Labrie F, Dupont A, Bélanger A, St.-Arnaud R, Giguére M, Lacourciere Y, Emond J, Monfette G: Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocr Rev 7:67-74, 1986.
16. Stege R, Eriksson A, Henriksson P, Carlström K: Orchidectomy or estrogen treatment in prostatic cancer: Effects on serum levels of adrenal androgens and related steroids. Int J Androl 10:581-587, 1987.
17. Hughes CL, Wall LL, Creasman WT: Reproductive hormone levels in gynecologic oncology patients undergoing surgical castration after spontaneous menopause. Gynecol Oncol 40:42-45, 1991.
18. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS: Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331:1056-1061, 1994.
19. Christiansen C, Riis BJ, Nilas L, Røbdro P, Deftos L: Uncoupling of bone formation and resorption by combined oestrogen and progestogen therapy in post-menopausal osteoporosis. Lancet ii:800-801, 1985.
20. Hassager C, Jensen LT, Johansen JS, Riis BJ, Melkko J, Pødenphant J, Risteli L, Christiansen C, Resteli J: The carboxy-terminal propeptide of type I procollagen in serum as marker of bone formation: The effect of nandrolone decanoate and female sex hormones. Metabolism 40:205-208, 1991.
21. Riis BJ, Johansen J, Christiansen C: Continuous oestrogen-progestogen treatment and bone mineral metabolism in post-menopausal women. Maturitas 10:51-58, 1988.